Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression profiling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptorspecific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.
Introduction
The ErbB family of receptor tyrosine kinases (RTKs) consists of four members: ErbB1 (EGFR, HER), ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4). Anomalous expression and/or activation of these receptors is observed in cancers of the breast, ovaries, nervous system, prostate, bladder, colon, head neck, and lung (Yarden and Sliwkowski, 2001) . ERBB2 is amplified in 15-30% of breast cancers, and its overexpression is associated with poor patient prognosis (Slamon et al., 1987; Hynes and Stern, 1994) . In contrast, ERBB4 overexpression is rare and its expression in breast cancer may be associated with more favorable clinical outcomes and a differentiated tumor grade Srinivasan et al., 1997; Knowlden et al., 1998; Vogt et al., 1998; Kew et al., 2000; Stern, 2000; Witton et al., 2003) . Co-overexpression of ERBB4 with ERBB2 in mammary carcinoma is associated with a more favorable clinical outcome, than is overexpression of ERBB2 alone (Suo et al., 2002) .
An oncogenic role for ERBB2, and a possible anticarcinogenic function associated with ERBB4, is further suggested by in vitro studies. In tissue culture, activation of ErbB2 is mainly associated with cellular proliferation and transformation (DiFiore et al., 1987; Muthuswamy et al., 2001; Penington et al., 2002) . Cellular responses to ErbB4 activation vary across cell lines. While ErbB4 can support proliferation, DNA synthesis, and transformation, in some mammary epithelial cell lines, it induces growth arrest and differentiation Cohen et al., 1996; Sartor et al., 2001; Williams et al., 2003) .
Furthermore, loss of ErbB2 and ErbB4 in the mammary gland is associated with different developmental phenotypes, with a requirement for ErbB2 in ductal outgrowth during puberty (Amy Jackson-Fisher/ DF Stern unpublished), and ErbB4 in ductal differentiation during late pregnancy and lactation (Tidcombe et al., 2003) . These phenotypic differences between the two receptors during normal development and in carcinogenesis suggest differences in the signaling pathways coupled to the two receptors.
Differential ErbB-driven signals can be achieved at several steps. Multiple growth factors activate one or more of these receptors (Riese and Stern, 1998) . Ligandactivated receptors form homo-as well as heterodimeric complexes with other ErbBs, thereby enabling the activation of a non-ligand-binding receptor. A hierarchy of dimerization combination preferences exists, in which ErbB2 is the favored partner Graus-Porta et al., 1997) . Each activated ErbB receptor has a unique repertoire of Tyr phosphorylation sites that facilitate coupling to an overlapping, but a distinct set of downstream signaling effectors (Olayioye et al., 2000; Yarden and Sliwkowski, 2001 ). Thus, the activating ligand, the available ErbB receptors, and preferential partner choice will influence receptor combinations activated and the specific signals generated.
A central question in signal transduction is how signal encoding occurs downstream of the various RTKs. For some RTKs, transcription profiling has been used to determine if differential activation of signaling pathways results in different combinations of transcriptional outputs. Surprisingly, some studies using this approach have concluded that the transcriptional response to RTK activation is qualitatively 'generic', and contains little receptor-specific information (Fambrough et al., 1999; Pawson and Saxton, 1999) . However, pathwayspecific mutations in the C. elegans EGFR result in distinct phenotypes (Lesa and Sternberg, 1997) and, in reconstructed systems, different combinations of ErbB receptors activate varying biological responses (Riese et al., 1995; Riese and Stern, 1998) .
Since transcriptional outputs are an important component of ErbB signaling, we determined if the pattern of transcriptional changes depends on the identity of the ErbB receptor activated. The different biological activities of ErbB2 and ErbB4, and their clinical importance, made a comparative study of transcriptional targets of these two receptors particularly attractive. Several studies have reported transcription profiles associated with overexpressed and/or activated ErbB2 (Oh et al., 1999; Wilson et al., 2002; Andrechek et al., 2003; Kumar-Sinha et al., 2003; Mackay et al., 2003) . Here, we compare the effects of acute activation of ErbB2 and ErbB4, using agonistic antibodies to forestall coactivation of other ErbBs.
Results

Agonistic antibodies activate homologous receptors and affect cellular growth
Most mammary epithelial cell lines express multiple ErbB receptors. Activating a single type of ErbB in mammary epithelial cells with physiological ligands is not possible, owing to the ability of these receptors to heterodimerize. As an alternative, we employed agonistic monoclonal antibodies to promote receptor homodimers. Agonistic ErbB4 antibody (ErbB4Ab) H77.1 promotes weak differentiation of MCF7 cells . The ErbB2 agonistic antibody (ErbB2Ab) N28 potentiates tumor growth in vivo (Stancovski et al., 1991) .
The human mammary carcinoma cell line T47D expresses moderate levels of all the four ErbB receptors (Graus-Porta et al., 1995) . ErbB4Ab and ErbB2Ab treatment of T47D cells induced tyrosine phosphorylation of the respective receptors ( Figure 1a , upper panel, compare lanes 3 with 1 and 5 with 4). ErbB4Ab activated ErbB4 comparably to levels of NRG near saturation for receptor phosphorylation (Figure 1a , upper panel, compare lanes 2 and 3). The agonistic antibodies did not crossactivate heterologous ErbBs (data not shown).
We next determined whether signaling induced by agonist antibody treatment of T47D cells is coupled to a biological response. Ribozyme-mediated downregulation of ErbB4 in T47D cells reduces colony growth in soft agar assays (Tang et al., 1999) . Consistent with this finding, ErbB4Ab treatment enhanced anchorage-independent colony formation to the same extent as NRG (NRG 2.7-fold; ErbB4Ab 2.9-fold) ( Figure 1b) . In monolayer culture, the ErbB4Ab inhibited cell growth, whereas ErbB2Ab, at the same concentration, induced proliferation (24% growth inhibition versus 8% growth induction; Figure 1c ), suggesting differences in the biological response associated with the two receptors.
ErbB4 and ErbB2 homodimers regulate target genes differentially
In order to determine the pattern of receptor-activated gene expression, cDNA preparations from T47D cells stimulated with ErbB4Ab or ErbB2Ab were compared with those from mock-treated cells. Transcription was evaluated 1-h post treatment, since pilot studies and earlier growth factor-profiling work indicated this as an optimal time point for detecting changes in immediate early genes (IEGs) (Fambrough et al., 1999; Perou et al., 1999; Sweeney et al., 2001 ). The labeled cDNA was Serum-starved T47D cells were stimulated with vehicle (mock), ErbB4 Ab-1 (ErbB4Ab), ErbB2 Ab-6 (ErbB2Ab), or NRG for 10 min at room temperature. Receptor-specific immunoprecipitations (IP) were performed and receptors were analysed by immunoblotting (blot) with anti-phosphotyrosine ('P-Tyr'). The filters were stripped and reprobed with receptor-specific antibodies to control for receptor loading ('receptor'). (b) Anchorageindependent growth of T47D cells incubated in vehicle (mock), NRG or ErbB4Ab for 2 weeks was measured. The fold increase in colony formation compared to mock is shown. Error bars represent s.e.m. from triplicate treatments. (c) Growth of T47D cells treated with ErbB2Ab and ErbB4Ab was compared with mock-treated cells using the MTT assay. The relative number of viable cells was determined by spectophotometry and the resultant OD (595 nm) for the three treatments is shown with error bars representing s.e.m. from triplicate treatments ErbB-regulated gene expression DN Amin et al hybridized to a 16 755-gene human oligonucleotide array (OHU16.7K). A gene was considered to be regulated if the geometric mean of ratios for experimental versus control, for three independent repeats of the experiment, was greater than 1.8-fold. This cutoff reflects a greater than 95% significance interval for the fold changes.
In all, 2.7% (456/16755) of the genes on the OHU16.7K array were scored as being upregulated with ErbB4Ab activation of T47D cells. ErbB2Ab treatment enhanced expression of 2.06% (348/16755) of the assayed genes compared to mock treatment. A complete list of genes upregulated by the two treatments is provided as supplemental data (Table S1 ). Activation of the two receptors yielded different gene expression profiles. A total of 248 genes were upregulated by more than 1.8-fold upon activation with both of the agonistic antibodies. For the purpose of comparison, genes were considered to be preferentially regulated by one receptor if their transcripts changed by greater than 1.8-fold with activation of one receptor and less than 1.4-fold with activation of the other receptor. In all, 40 genes were preferentially elevated by ErbB4 homodimerization, and 15 genes showed a bias towards upregulation by ErbB2Ab (Table 1) . Analyses from similar experiments performed using a 4600-gene cDNA microarray also revealed differential gene regulation by agonistic antibodies for the two receptors (data not shown).
Altogether, 0.07% (12/16755) and 0.23% (41/16755) of genes showed decreases in transcript level with ErbB4 or ErbB2 activation, respectively (complete lists are in Supplemental Data, Table S2 ). Once again, the two agonistic antibodies downregulated individual genes to different extents. ErbB2Ab treatment favored decreases in transcript levels for genes including phosphatidic acid phosphatase 2A (PPAP2A) and laminin b1, whereas ErbB4Ab had greater effects on genes including AMP-activated protein kinase and H-cadherin. ErbB-induced gene regulation resulted in fewer decreases than increases in transcript levels, consistent with the expression profile analyses of other RTKs (Dupont et al., 2001; Sweeney et al., 2001; Mulligan et al., 2002) .
Ligand identity can influence gene transcription
Two ErbB ligands, NRG1b and NRG2b, acting via a ErbB2 : 3 heteromer yield different gene-expression profiles (Sweeney et al., 2001) . We wished to determine whether different ligands acting via the same receptor could influence the expression of different genes. We addressed this question first in SUM44 breast carcinoma cells, which express ErbB2, ErbB3, and ErbB4 (Sartor et al., 2001) . In these cells, both NRG and HB-EGF increase ErbB4 phosphorylation, but the latter induces weaker receptor activation (Figure 2a , compare lanes 2 and 3 with 1). Gene-expression profiling of SUM44 cells treated with these two natural agonists and the ErbB4 agonistic antibody was performed using a 4600-gene cDNA array (Hu4.6K cDNA array). Genes were scored as being upregulated if the geometric means from three independent experiments showed transcript changes greater than 1.4-fold (a cutoff based on greater than 95% significance interval). Table 2 lists the top 20 genes upregulated by each of the three ErbB4 agonists (complete list of regulated genes available as supplemental data, Table S3 ). Although, there were genes upregulated by both NRG and HB-EGF (shown in bold), transcription of genes such as Endoglin and Rho GAP9 was elevated to a greater extent with HB-EGF than with NRG (Table 2 ). ErbB4Ab treatment of SUM44 cells also resulted in overlapping, but different sets of regulated genes compared to transcripts induced by NRG.
It is possible that the ligand-dependent differences in gene-expression profiles observed in the SUM44 cells arise from differential homo-versus heterodimer signaling linked to HB-EGF and NRG, respectively (Sartor et al., 2001) . Alternatively, the differences in gene expression could be a result of different levels of receptor phosphorylation induced by the two agonists ( Figure 2a ). To address these possibilities, we analysed human CEM/4 cells, a lymphoid line engineered to express ErbB4 in the absence of other ErbBs (Plowman et al., 1993) . Both NRG and ErbB4Ab induced similar levels of tyrosine phosphorylation of ErbB4 (Figure 2b ). Hu4.6K cDNA arrays were used to analyse gene expression regulated by NRG and ErbB4Ab ligated to ErbB4 homomers. The top 20 genes upregulated by the two treatments are reported in Table 3 (complete list of upregulated genes available as supplemental data, Table S4 ). The top 20 genes upregulated by the two ErbB4 agonists have only five genes in common (shown in bold). Hence, two different ligands activating a single type of ErbB receptor can influence gene transcription differentially.
Validation of microarray results
Microarray analyses are susceptible to artifacts arising from mechanical arraying problems, handling errors, annotation problems, and, in the case of cDNA arrays, clone mixtures or chimeric clones. Results from sequence verification of a subset of clones spotted on the Hu4.6K cDNA arrays are provided as supplemental data (Table S5 ). Our error rate of 27% for misidentified clones on the Hu4.6K cDNA array was within the range of previously reported error rates of 20-38% (Ross et al., 2000; Halgren et al., 2001; Taylor et al., 2001) .
Changes in transcript levels for a subset of candidate genes identified from the oligonucleotide microarray analyses were measured by quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR). Two genes, RAB2 and EPS15R (identified in Table 1 in bold), which were scored as being preferentially induced by ErbB4Ab treatment, were assayed by QRT-PCR as was GATA4, which was induced by 1.78-fold upon ErbB4Ab treatment of T47D cells. The QRT-PCR results confirmed the preferential induction of these genes through ErbB4 signaling ( Figure 3 , upper panel). Table 1 in bold) and PPAP2A, which were preferentially up-and downregulated by ErbB2Ab, respectively, were also confirmed by QRT-PCR as being specific to ErbB2 activation ( Figure 3 Fambrough et al. (1999) indicated that activation of platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor, or EGFR resulted in nearly identical patterns of gene regulation. More recently, it has been shown that insulin receptor and insulin-like growth factor receptor-1 regulate an overlapping but distinct group of genes (Dupont et al., 2001 (Dupont et al., , 2003 Mulligan et al., 2002) . Similar results have now been observed between TGFb receptors, ALK1 and ALK5, and two isoforms of the progesterone receptor (Ota et al., 2002; Richer et al., 2002) . Within the ErbB family, overexpression of individual types of ErbBs also results in receptor-specific gene expression (Alaoui-Jamali et al., 2003) . The results presented here, that ErbB2 and ErbB4 preferentially regulate distinct targets, supports a model of receptordependent signaling specificity.
HRY (identified in
Receptor-generated specificity within the ErbB family may be achieved by modulating the potency and duration of signaling, or by activating qualitatively different signaling pathways (Marshall, 1995) . NRG and EGF, acting via different ErbB receptor combinations, signal through the MAPK, p38, PKC, and PI3K pathways with different strengths and kinetics (Sweeney et al., 2001; Neve et al., 2002) . ErbB1 endocytosis occurs much more rapidly than endocytosis of the other ErbB receptors . ErbB2 and ErbB4 cleavage have different requirements for PKC signaling (Pupa et al., 1993; Vecchi et al., 1996) . It is plausible that differences in ErbB2 and ErbB4 internalization and cleavage may influence the potency and duration of effector pathways (Lenferink et al., 1998; Waterman et al., 1998) . Interactions of the ErbBs with distinct signaling molecules can occur through differences in autophosphorylation sites and via distinct subcellular localization of the signaling receptors (Olayioye et al., 2000; Yarden and Sliwkowski, 2001; Zhou and Carpenter, 2002) .
Our data further indicate that the activating ligand is able to modulate the signaling from a single ErbB receptor type. In CEM/4 cells, activation of ErbB4 homodimers by different ligands leads to qualitative differences in the phosphorylation of the receptor and coupling to downstream targets (Sweeney et al., 2000) . Using the same cell line, we found that two ligands, NRG and ErbB4Ab, activating ErbB4 to a similar extent, can differently influence transcriptional outcomes. Activation of one receptor combination with different ligands not only couples the receptors to distinct biochemical pathways, but also elicits varying cellular outcomes, supporting the possibility that the differences in gene expression observed in our study may have functional significance (Hobbs et al., 2002) . For example, multiple EGFR ligands show temporal overlap in their expression patterns during mouse mammary gland development (Schroeder and Lee, 1998) . Our results suggest that, instead of playing redundant roles, individual agonists may be responsible for initiating unique molecular programs that then dictate specific cellular outcomes. Examples of ligand-dependent qualitative differences in gene regulation are also observed outside the RTK superfamily between interferon b1 and interferon a2a, which engage a common receptor (da Silva et al., 2002) .
Mutational analysis of the juxtamembrane region of the extracellular domain of ErbB2 suggests that transformation by the constitutively dimerized receptors occurs only when they are complexed in specific geometric configurations (Burke and Stern, 1998) . Since binding of EGF agonists dramatically alters the conformation of the EGFR (Ferguson et al., 2003) , it is quite possible that there are agonist-associated specificities in EGFR conformation or equilibrium between inactive and active forms. This could influence phosphorylation site selection that would differentially influence substrate selection and/or subcellular localization and turnover (Decker, 1990) .
We also observed differential gene-expression profiles regulated by NRG, HB-EGF, and ErbB4Ab activation of ErbB4 in SUM44 breast cancer cells. Our CEM/4 data suggest that the differences may be accounted for by ligand-driven specificity. In this study, receptors were activated with high doses of ligands that yielded similar levels of receptor phosphorylation, so we did not evaluate the impact of different levels of receptor activation on transcriptional output. The weaker receptor activation elicited by HB-EGF in SUM44 cells compared to NRG induction may contribute to (Sartor et al., 2001) . Hence, differences arising from homomeric versus heteromeric signaling may also contribute to distinct patterns of gene regulation (Olayioye et al., 1998) . In fact, heterodimers of ErbBs overexpressed in NIH3T3 cells result in overlapping but distinct expression profiles from single-receptor homodimers (Alaoui-Jamali et al., 2003) . Our study mainly identified targets of ErbB4 and ErbB2 homodimer activation. Although, ErbB signaling in vivo generally includes formation of heterodimers (Gassmann et al., 1995; Lee et al., 1995) , ErbB4 homodimer signaling may be important during hindbrain development (Tidcombe et al., 2003) . Differences in signaling targets of homo-versus heterodimeric activation are especially intriguing in the case of ErbB2. In mammary carcinoma, ERBB2 can be activated by multiple mechanisms, including overexpression, which will induce ligand-independent homodimerization, and autocrine activation through heterodimerization with other ErbBs (Stern, 2000) . The results presented here suggest that these different modes of activation may be associated with differential regulation of signaling pathways, which could influence the clinical outcomes.
The differential response of T47D cells to agonist ErbB2 and ErbB4 antibodies parallels similar work with growth factors (Figure 1 , Sartor et al., 2001; Penington et al., 2002; Williams et al., 2003) . In these experiments, receptor activation was at similar levels to that observed with near saturating levels of NRG. However, we cannot rule out the possibility that the Genes were scored as being upregulated if their geometric mean ratio was greater than 1.4-fold. Genes shown in bold were upregulated in common with NRG ErbB-regulated gene expression DN Amin et al functional and transcriptional differences observed in our experiments could be due to a stronger phosphorylation of ErbB2 compared to that of ErbB4. However, our data are in agreement with other studies reporting an antiproliferative response associated with ErbB4 activation in comparison to ErbB2 activation. A number of ErbB2 targets identified in this study are abnormally expressed in tumors, making them good candidates for diagnostic and prognostic markers. An increase in transcription of RNA encoding Claudin 4, a tight-junction protein, is associated with ErbB2 homodimerization. Increased Claudin 4 levels are observed in ovarian tumors compared to ovarian cystadenomas (Rangel et al., 2003) . Hairy drosophila homologue (HRY/HES1) is a basic helix loop helix transcription factor that is a target of Notch signaling (Sasai et al., 1992; Ohtsuka et al., 1999) . Notch1 expression is observed in breast tumors, but is minimal in normal breast tissue (Weijzen et al., 2002) . Both EGF and NRG induce HRY expression in breast tumor cells (Sweeney et al., 2001; Hirata et al., 2002) . Transcript levels for the phosphatase PTPN6/SHP-1 are increased upon ErbB2Ab treatment. SHP-1 levels are high in breast tumors and its expression is correlated with expression of GRB2, a key mediator of ErbB2 signaling (Yip et al., 2000) .
Since ErbB2 and ErbB4 regulate key morphogenetic events in the developing mammary gland, we were also interested in identifying ErbB target genes with known functions or regulated expression in mammary tissue (Stern, 2003) . ErbB2Ab induction of b-casein is consistent with reduced levels of this milk protein in NRGa knockout mammary glands (Li et al., 2002) , and lactational differentiation defects in mice expressing dominant-negative ErbB2 . The ErbB4 target CSF1R (encoded by c-fms) is expressed preferentially in mammary glands of pregnant and lactating mice, coinciding with ErbB4 expression and function (Sapi et al., 1998; Schroeder and Lee, 1998; . Mice homozygous for an inactivating mutation of CSF-1, the ligand for the CSF1R, display defects during lactation (Pollard and Hennighausen, 1994) . Cezanne is a zinc-finger-binding protein that suppresses NF-kappa B transcription (Evans et al., 2001) . In the developing mammary gland, NF-kappa B activation antagonizes Stat5-mediated b-casein induction (Geymayer and Doppler, 2000) . Thus, an ErbB4-mediated increase in Cezanne transcript levels might potentiate Stat5 signaling in the mammary gland, which is regulated in part through ErbB4 . ErbB4 preferentially induced Rab2, a small G-protein, which promotes vesicle formation from pre-Golgi intermediates (Tisdale, 1999) . It will be of interest to determine if ErbB4 induction of Rab2 influences milk secretion in the mammary gland, as has been proposed for NRG-induced milk secretion via transcriptional regulation of Rab3A (Vadlamudi et al., 2000) .
This study is the first description of IEG targets of endogenously expressed ErbB2 and ErbB4 activated singly. We have identified candidate receptor targets that may mediate ErbB-dependent morphogenesis of the mammary tissue. In addition, transcriptional regulation by ErbB2 may be important in mammary carcinogenesis. Since signaling differences between these ErbBs and other receptor kinases may have important diagnostic and therapeutic implications, and since receptor-directed drugs are under development or in clinical use, it will be important to evaluate the activity of individual receptors in tumor biopsy specimens. One strategy relies on receptor-specific phospho-antibodies. As an alternative approach, some of the gene targets identified here may become useful as signature receptor-specific markers for signaling during normal development and oncogenesis.
Materials and methods
Cell culture
T47D and CEM/4 cells were maintained in RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2 mM L-glutamine. T47D medium was supplemented with bovine insulin at 5 mg/ml and the CEM/4 medium with 200 mg/ml Geneticin. MCF7 cells were maintained in minimum essential medium-a supplemented 10% FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate. The cells were cultured at 371C in 5% CO 2 . SUM44 cells were generously provided by Dr S Ethier (University of Michigan, Ann Arbor, MI, USA), and were maintained in serum-free Ham's F-12 supplemented with 0.1% bovine serum albumin, 5 mg/ml gentamycin, 5 mM ethanolamine, 10 mM HEPES, 5 mg/ml transferrin, 10 mM T3, 50 mM selenium, 5 mg/ml insulin, and 1 mg/ml hydrocortisone. SUM44 cells were maintained at 371C in 10% CO 2 . Cells were grown to confluency in 100 mm plates or at 1 Â 10 6 cells/ml (CEM/4), and switched to serum-free media for 24 h prior to stimulation.
Immunoprecipitation and immunoblotting
Stimulations were performed with vehicle (Dulbecco's phosphate-buffered saline with Ca 2 þ and Mg 2 þ , containing 0.1%. bovine serum albumin, ErbB4 Ab-1 H77.1 (NeoMarkers, Fremont, CA, USA; 10 mg/ml), ErbB2 Ab-6 N28 (Stancovski et al., 1991 ) (NeoMarkers; 10 mg/ml), NRGb1 (R&D Systems, Minneapolis, MN, USA; 50 ng/ml), or HB-EGF (R&D Systems, Minneapolis, MN, USA; 100 ng/ml) for 10 min at room temperature. ErbB receptor phosphorylation was detected as described previously . Briefly, receptors were immunoprecipitated from cell lysates and processed for immunoblotting. ErbB2 and ErbB4 were immunoprecipitated and immunoblotted with SC-284 and SC-283 antibodies, respectively (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Tyrosine phosphorylation was detected by immunoblotting with mAb 4G10 (Upstate, Lake Placid, NY, USA).
Soft agar assays
An underlay of 0.7% agar in DMEM, 5 mg/ml insulin, and 10% FBS was prepared in 35 mm plates. In all, 10 000 T47D cells were plated in an overlay of 0.35% agar in DMEM supplemented with 5 mg/ml insulin and 10% FBS. Vehicle only, ErbB4 Ab-1 at 10 mg/ml, or NRG-b1 at 50 ng/ml were added to the overlay. The colonies were allowed to form over 2 weeks at 371C, 5% CO 2 . Colonies were stained overnight at 371C with p-iodonitrotetrazolium violet (Sigma, St Louis, MO, USA) at 1 g/l in 20 mM HEPES (pH 7.4). The plates were scanned and the images imported into TotalLab software, which then determined colony numbers on the image (Nonlinear Dynamics, Madison, WI, USA). Each treatment was performed in triplicate.
MTT assay
In total, 2 Â 10 3 cells/well were seeded in 96-well plates and allowed to adhere overnight. Cells were either mock-treated or treated with 10 mg/ml of the agonistic antibodies in media containing 0.1% serum for 3 days. Each treatment was performed in triplicate. Cell growth was determined using the Cell Proliferation Kit 1 (Roche, Indianapolis, IN, USA), according to the manufacturer's instructions. Results were quantified by spectrophotometry using a BioRad 3550-UV microplate reader at a wavelength 595 nm.
Oligonucleotide and cDNA arrays
A total of 4608 gene human cDNA arrays (Hu4.6K) and 16 755-gene oligonucleotide human arrays (OHU16.7K) printed on glass slides were obtained from the Keck DNA Microarray Resource, Yale University. The cDNA arrays consisted of sequence-verified clones obtained from Research Genetics (Huntsville, AL, USA). Approximately 39% of the genes are ESTs. These arrays were spotted in tandem duplicates for each clone. The OHU16.7K arrays consist of 70mer oligonucleotides representing 16 659 genes from the Operon Oligo Set Version 1.1 and 96 genes from Compugen spotted singly. Both cDNA and oligonucleotide array gene sets are described at http://info.med.yale.edu/wmkeck/dna_ar-rays.htm. Prior to use, DNA on the Hu4.6K cDNA slides was denatured at 761C for 2 min. Slides were prehybridized at 421C in 35% formamide, 4 Â SSPE, 2.5 Â Denhardt's reagent and 0.2 mg/ml single-stranded salmon sperm DNA containing solution for 2 h. The prehybridization solution was drained from the slides and the probe was applied to the array.
Probe preparation and hybridization for microarray experiments
Serum-starved cells prepared as above were incubated with vehicle, A ErbB4 Ab-1, ErbB2 Ab-6, or NRG-b for 1 h at 371C. Total cellular RNA was isolated using the RNEasy miniprep kit (Qiagen, Valencia, CA, USA), with an on-column DNAse treatment step, according to the manufacturer's instructions. A measure of 40-50 mg of total RNA was reverse transcribed using Superscript II reagents (Invitrogen, Carlsbad, CA, USA) containing either Cy3-dUTP or Cy5-dUTP (1 mM) for 2 h at 421C. After labeling, the RNA was hydrolysed using EDTA (55.6 mM) and NaOH (181.8 mM). The probe was neutralized with Tris-HCl pH 7.4 (312.5 mM). The unincorporated label was removed using Centricon YM-30 spin columns. For the cDNA arrays, the probe was added to 35% formamide, 0.5% SDS, 2.5 Â Denhardt's reagent and 4 Â SSPE, 0.1 mg/ml poly dA, 2 mg/ml yeast tRNA, and 10 mg/ml human Cot1 DNA. The probe was denatured by incubation at 981C for 2 min and then allowed to prehybridize at 421C for 1 h prior to hybridization to the array. The slides were hybridized at 421C for 20 h in humidified hybridization chambers (Gene Machines, San Carlos, CA, USA). For the OHU16.7K arrays, the probe was added to 0.8 Â SSPE, 2.56 Â SSC, 0.2% SDS, and 0.66 mg/ml poly dA, and hybridized to slides at 631C for 20 h. After hybridization, slides were washed in 1 Â SSC containing 0.1% SDS, followed by 0.2 Â SSC and 0.05 Â SSC. The slides were dried by centrifuging and scanned.
Scanning, data acquisition, and analysis
Slides were scanned using GenePix 4000A (Axon Instruments, Union City, CA, USA) at 532 nm (Cy3) and 635 nm (Cy5) wavelengths. The scanned images were imported into GenePix Pro 3.0 software for data acquisition. The data were exported to Microsoft Excel. Prior to further analysis, spots that were removed from analysis (i) if they were flagged as 'not found', or (ii) if Cy3 or Cy5 mean spot intensities were less than mean background intensity plus 3 standard deviations (s.d.) for the OHU16.7K array, or 2 s.d. for the Hu4.6K cDNA array. Ratios of Cy5 : Cy3 (experimental: control) were obtained, based on the normalized background subtracted median values. Lowess curve fit was performed to normalize the data for the two dyes (BRB-array software, NIH, Bethesda, MD, USA) (Tseng et al., 2001) . Each experiment was repeated using three independent sources of RNA to control for interexperimental variability. Geometric means were obtained for ratios across three independent repeats.
Quantitative real-time reverse transcriptase-polymerase chain reaction (QRT-PCR)
A measure of 5 mg of total RNA was reverse-transcribed using Superscript II (Invitrogen). Dilution (1 : 100) of the cDNA obtained was subjected to quantitative real-time amplification on the I-Cycler (BioRad, Hercules, CA, USA), using the Quantitect Sybr Green PCR kit (Qiagen). Primer sequences are reported in Table 4 . Amplification cycles consisted of an initial 15 min at 951C and then 35-40 cycles at 941C for 1 min, 461C for 1 min, and 721C for 1 min. Analysis was performed using the I-Cycler optical interface version 2.3 (BioRad). Melt curve analysis was performed to ensure that single products had been amplified. Reactions lacking reverse transcriptase were performed to control for genomic DNA amplification. Relative standard curves for each of the genes were obtained by performing two-fold dilutions of a cDNA pool. The relative concentrations were obtained for each gene under each treatment. The relative concentrations were normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels. Fold changes were obtained relative to mock treatment for ErbB4Ab, ErbB2Ab, and NRG-stimulated RNA. Each experiment was repeated using three independent sources of RNA and, within each experimental repeat, amplifications were performed in triplicate. The average fold change ratio and the standard error of the mean (s.e.m.) were determined.
